BrainVectis adds Huntington’s disease gene therapy candidate to AskBio’s program
Read the press release:Â AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases_FINAL 22Apr2020
https://www.france.tv/france-2/vivement-dimanche/1151551-vivement-dimanche.html
She presented a conference untitled :Â gene therapysytrategies for neurodegenerative diseases : from genetic to complex diseases
Brainvectis received the Orphan Drug Designation (ODD) from the European Commission for BV-CYP01, its gene therapy drug candidate for the treatment of Huntington’s disease.
Brainvectis will participate in the European Society of Gene and Cell Therapy, that will be held at Lausanne, Switzerland.
Nathalie Cartier will give an oral presentation on Tuesday 16th October during the CNS session entitled « Gene Therapy for Huntington’s disease ».
Sandro Alves will give an oral presentation on friday 19th October during the CNS session entitled « CYP46A1 gene therapy alleviates spinocerebellar ataxia in mouse models ».
Sandro Alves participated in the Gene Therapy partnering day, held at the Institut des Maladies Génétiques, organized by Medicen/Imagine (Paris). Sandro Alves introduced Brainvectis in the session « Innovative Technological Solutions » as an example of start-up translating academic preclinical research into industrial development.
Â
Brainvectis has closed a financing round of € 1.1 million from private investors. The funds will allow the company to move forward its programs while preparing a next financing operation in 2018.
On november 21st, Head of preclinical research Dr. Sandro Alves presented Brainvectis as an example of spin-off translating academic preclinical research into industrial development.
NeurATRIS is a research infrastructure conceived to accelerate the translation of discoveries in basic research into medical innovations for the treatment of diseases of the nervous system.
